GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 14.89 Billion KRW | 0.22% |
| 2022 | 14.86 Billion KRW | 39.07% |
| 2021 | 10.68 Billion KRW | 28.78% |
| 2020 | 8.29 Billion KRW | -5.11% |
| 2019 | 8.74 Billion KRW | 11.72% |
| 2018 | 7.82 Billion KRW | 13.84% |
| 2017 | 6.87 Billion KRW | -2.0% |
| 2016 | 7.01 Billion KRW | 1.8% |
| 2015 | 6.89 Billion KRW | 12.37% |
| 2014 | 6.13 Billion KRW | -0.15% |
| 2013 | 6.14 Billion KRW | -9.64% |
| 2012 | 6.79 Billion KRW | -9.39% |
| 2011 | 7.5 Billion KRW | 89.89% |
| 2010 | 3.95 Billion KRW | -12.87% |
| 2009 | 4.53 Billion KRW | -23.76% |
| 2008 | 5.94 Billion KRW | 61.94% |
| 2007 | 3.67 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 15.97 Billion KRW | 7.24% |
| 2024 Q2 | 16.5 Billion KRW | 3.28% |
| 2023 Q1 | 16 Billion KRW | 7.7% |
| 2023 Q2 | 16.03 Billion KRW | 0.2% |
| 2023 FY | 14.89 Billion KRW | 0.22% |
| 2023 Q3 | 15.54 Billion KRW | -3.12% |
| 2023 Q4 | 14.89 Billion KRW | -4.14% |
| 2022 Q1 | 11.76 Billion KRW | 10.05% |
| 2022 Q3 | 16.29 Billion KRW | 10.45% |
| 2022 Q4 | 14.86 Billion KRW | -8.78% |
| 2022 FY | 14.86 Billion KRW | 39.07% |
| 2022 Q2 | 14.75 Billion KRW | 25.43% |
| 2021 FY | 10.68 Billion KRW | 28.78% |
| 2021 Q1 | 8.76 Billion KRW | 5.59% |
| 2021 Q2 | 9.64 Billion KRW | 10.07% |
| 2021 Q3 | 10.31 Billion KRW | 6.96% |
| 2021 Q4 | 10.68 Billion KRW | 3.6% |
| 2020 FY | 8.29 Billion KRW | -5.11% |
| 2020 Q2 | 10.29 Billion KRW | 9.57% |
| 2020 Q3 | 9.1 Billion KRW | -11.58% |
| 2020 Q4 | 8.29 Billion KRW | -8.87% |
| 2020 Q1 | 9.4 Billion KRW | 7.48% |
| 2019 Q1 | 8.55 Billion KRW | 9.29% |
| 2019 FY | 8.74 Billion KRW | 11.72% |
| 2019 Q3 | 9.3 Billion KRW | 6.71% |
| 2019 Q2 | 8.72 Billion KRW | 1.95% |
| 2019 Q4 | 8.74 Billion KRW | -6.04% |
| 2018 Q3 | 8.1 Billion KRW | 4.83% |
| 2018 Q4 | 7.82 Billion KRW | -3.41% |
| 2018 Q2 | 7.73 Billion KRW | 6.38% |
| 2018 Q1 | 7.26 Billion KRW | 5.69% |
| 2018 FY | 7.82 Billion KRW | 13.84% |
| 2017 FY | 6.87 Billion KRW | -2.0% |
| 2017 Q4 | 6.87 Billion KRW | -5.41% |
| 2017 Q3 | 7.26 Billion KRW | -0.48% |
| 2017 Q2 | 7.3 Billion KRW | 5.62% |
| 2017 Q1 | 6.91 Billion KRW | -1.44% |
| 2016 Q2 | 7.38 Billion KRW | 9.99% |
| 2016 FY | 7.01 Billion KRW | 1.8% |
| 2016 Q4 | 7.01 Billion KRW | -1.84% |
| 2016 Q3 | 7.14 Billion KRW | -3.24% |
| 2016 Q1 | 6.71 Billion KRW | -2.57% |
| 2015 FY | 6.89 Billion KRW | 12.37% |
| 2015 Q4 | 6.89 Billion KRW | -5.01% |
| 2015 Q3 | 7.25 Billion KRW | 7.95% |
| 2015 Q2 | 6.72 Billion KRW | 0.75% |
| 2015 Q1 | 6.67 Billion KRW | 8.77% |
| 2014 Q3 | 6.63 Billion KRW | 0.7% |
| 2014 Q2 | 6.58 Billion KRW | 0.49% |
| 2014 Q1 | 6.55 Billion KRW | 6.74% |
| 2014 FY | 6.13 Billion KRW | -0.15% |
| 2014 Q4 | 6.13 Billion KRW | -7.56% |
| 2013 FY | 6.14 Billion KRW | -9.64% |
| 2013 Q4 | 6.14 Billion KRW | 0.76% |
| 2013 Q3 | 6.09 Billion KRW | -3.7% |
| 2013 Q2 | 6.33 Billion KRW | -1.52% |
| 2013 Q1 | 6.42 Billion KRW | -5.44% |
| 2012 Q4 | 6.79 Billion KRW | 0.0% |
| 2012 FY | 6.79 Billion KRW | -9.39% |
| 2012 Q1 | 3.78 Billion KRW | 0.0% |
| 2011 FY | 7.5 Billion KRW | 89.89% |
| 2011 Q3 | 4.87 Billion KRW | 13.78% |
| 2011 Q2 | 4.28 Billion KRW | 4.6% |
| 2011 Q1 | 4.09 Billion KRW | 0.0% |
| 2010 Q1 | 3.25 Billion KRW | 0.0% |
| 2010 FY | 3.95 Billion KRW | -12.87% |
| 2010 Q3 | 3.92 Billion KRW | 15.49% |
| 2010 Q2 | 3.4 Billion KRW | 4.6% |
| 2009 FY | 4.53 Billion KRW | -23.76% |
| 2009 Q3 | 4.17 Billion KRW | -5.71% |
| 2009 Q2 | 4.42 Billion KRW | -12.85% |
| 2009 Q1 | 5.07 Billion KRW | -14.7% |
| 2008 Q1 | 3.9 Billion KRW | 6.35% |
| 2008 Q2 | 4.81 Billion KRW | 23.36% |
| 2008 Q3 | 5.3 Billion KRW | 10.11% |
| 2008 Q4 | 5.94 Billion KRW | 12.1% |
| 2008 FY | 5.94 Billion KRW | 61.94% |
| 2007 Q2 | 3.28 Billion KRW | -3.28% |
| 2007 FY | 3.67 Billion KRW | 0.0% |
| 2007 Q4 | 3.67 Billion KRW | -8.23% |
| 2007 Q3 | 4 Billion KRW | 22.0% |
| 2007 Q1 | 3.39 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ORIENT BIO Inc. | 3.65 Billion KRW | -307.643% |
| Green Cross Holdings Corporation | 579.72 Billion KRW | 97.43% |
| Green Cross Holdings Corporation | 516.24 Billion KRW | 97.114% |
| Pharmicell Co., Ltd. | 20.87 Billion KRW | 28.628% |
| Green Cross Corporation | 516.24 Billion KRW | 97.114% |
| Celltrion, Inc. | 3041.45 Billion KRW | 99.51% |
| Samsung Biologics Co.,Ltd. | 2641.36 Billion KRW | 99.436% |
| SK bioscience Co.,Ltd. | 80.64 Billion KRW | 81.529% |
| SK Biopharmaceuticals Co., Ltd. | 102.52 Billion KRW | 85.47% |
| Prestige BioPharma Limited | 18.1 Billion KRW | 17.71% |